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The safety and efficacyof incremental doses of diltiazem
in treating angina pectoris were assessed in 20 patients
with functional class II to III exertional angina. During
an initial single-blind dose titration phase, diltiazem
produced a dose-related improvement in anginal fre-
quency and exercise capacity. Weekly anginal attacks
were reduced to 7.5 ± 8.9,5.6 ± 7.8 and 4.9 ± 7.3 on
diltiazem, 120, 240 and 360 mg per day, respectively,
as compared with 11.9 ± 8.7 on placebo (all p < 0.001).
Treadmill time was significantly enhanced by high dose
(360 mg per day) as compared with moderate dose (240
mg per day) diltiazem: 473 ± 149 versus 424 ± 146
Diltiazem, a calcium entry blocking agent, has been shown
to be effective for the treatment of angina due to coronary
spasm and obstructive coronary disease 0-14). Recent stud-
ies (5-12) demonstrated that diltiazem decreases the fre-
quency of anginal attacks and improves exercise tolerance
when given in doses up to 240 mg a day.
The present study was undertaken to evaluate the com-
parative efficacy, safety and tolerance of diltiazem when
given in a higher daily dose of 360 mg to patients with
exertional angina.
Methods
Study group. The study group consisted of 20 men,
whose mean age was 58 years (range 43 to 67), enrolled
from November 1981 through June 1982. All patients suf-
fered from chronic stable angina and were in functional class
II or III (5). Fifteen patients had coronary artery disease
documented by coronary angiography or a prior myocardial
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seconds (p < 0.05). Time to ischemic ST segment depres-
sion was similarly changed: 344 ± 132 versus 298 ±
142 seconds (p < 0.05) by high dose as compared with
moderate dose diltiazem.
During a subsequent double-blind phase, high dose
diltiazem significantly reduced weeklyanginal frequency
when compared with placebo: 3.1 ± 3.0 versus 9.3 ±
7.1 (p < 0.001); and increased treadmill exercise time:
508 ± 158 versus 418 ± 172 seconds on placebo (p <
0.05). Subjective and objective benefits of high dose dil-
tiazem were sustained during a follow-up period of 6
months without major drug side effects.
infarction. None had symptoms suggestive of coronary vaso-
spasm. Criteria for entry into the study required that each
patient experience at least five episodes of angina per week
in addition to demonstrating myocardial ischemia on ex-
ercise testing. The latter was defined as at least 1 mm of
additional ST segment depression lasting 0.08 second after
the J point, associated with exercise-induced angina, com-
pared with the standing rest tracing. No patient had conges-
tive heart failure, myocardial infarction within 3 months,
valvular or congenital heart disease, thyrotoxicosis, anemia,
noncardiac causes of chest pain or renal, hepatic or endo-
crine disease. All patients signed an informed consent form
approved by the Institutional Review Board at Boston Uni-
versity Medical Center.
Study design. All antianginal medications were discon-
tinued in each patient at least 48 hours before entering the
study. Patients were allowed to consume nitroglycerin as
needed for anginal attacks, but were instructed not to take
any prophylactically.
The protocol consisted of a single-blind placebo-con-
trolled dose titration phase (phase I), followed by a ran-
domized double-blind crossover phase (phase II) and finally
by an open label chronic phase (phase III) (Fig. 1). Patients
were evaluated weekly during the first two phases and then
during weeks 2, 4, 8, 16 and 24 of the third phase by the
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same study nurse and one of two physicians. Evaluation
included a physical examination, electrocardiogram at rest,
hematologic and biochemical profile, urinalysis and tabu-
lation of frequency of anginal attacks and nitroglycerin con-
sumption. Patient compliance was verified by counting study
tablets and measuring blood levels.
Phase I consisted of a 2 week placebo period followed
by a 3 week dose titration phase during which patients
received diltiazem in daily doses of 120, 240 and 360 mg
for 1 week each, respectively, in an attempt to ascertain the
maximally tolerated dose for each patient. All patients tol-
erated the highest dose of diltiazem. The patients then re-
ceived placebo for 1 week before entering the double-blind
phase of the study.
Phase II was a 6 week randomized double-blind cross-
over phase during which either diltiazem, 90 mg, or placebo
was given four times a day for 2 week periods. After each
2 week period, placebo was administered for a 1 week
period. During phase III, each patient continued the daily
360 mg diltiazem dose for 6 months.
Exercise testing. Ten treadmill exercise tests were per-
formed during the 12 weeks of phases I and II, and four
additional tests were performed during phase III using a
modification of the Bruce protocol (Fig. 1). A 3 minute
warm-up stage (1. 7 mph and 5% grade) was followed by
the standard Bruce protocol (16). A 12 lead electrocardio-
gram was recorded at rest and at 1 minute intervals during
exercise and recovery until the ST segments and heart rate
resembled the baseline tracing. Blood pressure was recorded
at rest, at the end of each stage of exercise, at the onset of
angina and during recovery. The patients exercised to a
symptom-limited end point consisting of either moderate
angina, dyspnea or fatigue.
Variables analyzed on the exercise tests included: total
exercise time, time to onset of angina, time to 1 mm of
additional ST depression and heart rate, blood pressure and
rate-pressure product at rest, at the end of the first 3 minutes
of exercise (submaximal) and at maximal exercise. All tests
were performed 2 hours after the last dose of study medi-
cation was administered.
Blood levels. Diltiazem blood levels were determined
weekly during phase I. Blood samples were drawn 2 hours
after administration of the last dose of study medication.
Plasma diltiazem concentration was measured by gas chroma-
tography (17).
Statistical analyses. A one-way analysis of variance for
repeated measures was used to determine if there were sig-
nificant differences in the group mean values. Ifthe analysis
of variance indicated a significant difference, a two-tailed,
paired Student's t test was then applied to the data. Prob-
ability (p) was considered significant at the < 0.05 level.
All values are expressed as mean ± 1 standard deviation.
Results
Blood levels and dosage of diltiazem. Mean plasma
levels during treatment with 120, 240 and 360 mg per day
were 93 ± 35, 183 ± 63 and 274 ± 102 ng/ml, respectively
(p < 0.001). A five-fold difference in the plasma levels was
observed after a given dose. Diltiazem levels did not cor-
relate with improvement in exercise tolerance or decrease
in anginal frequency.
Effect on angina (Table 1). Anginal frequency during
the single-blind phase was significantly reduced by 41, 59
and 61% during treatment with 120, 240 and 360 mg per
day of diltiazem, respectively (p < 0.001 compared with
placebo for all doses). During the double-blind phase, an-
ginal attacks were decreased by 66% when patients were
taking diltiazem, 360 mg per day (p < 0.001). Similarly,
the number of nitroglycerin tablets required per week de-
creased significantly with all doses of diltiazem.
Effect on hemodynamics (Table 1). The mean heart
rate at rest was 87 ± 16 beats/min when the patients were
taking placebo during the single-blind phase. Diltiazem in
doses of 240 and 360 mg/day resulted in a reduction of heart
rate to 79 ± 14 and 80 ± 14 beats/min, respectively (p <
0.05). During the double-blind phase, the heart rate at rest
was likewise reduced by diltiazem. The systolic blood pres-
sure at rest was significantly altered only by the highest dose
of diltiazem during the single-blind phase. When the rate-
pressure product was analyzed, both 240 and 360 mg per
day caused a significant reductionin the rate-pressureproduct.
The heart rate and rate-pressure product during sub-
maximal exercise were measured to be significantly less with
Figure 1. Protocol design. ETT =
exercise treadmill test.
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Table 1. Results of the Single-Blind and Double-Blind Crossover Comparison
Single-Blind Double-Blind
Diltiazem
120 mg/day 240 mg/day
75 ± 8.9t 5.6 ± 7 st
5.5 ± 8.8:\: 3.8 ± 77:\:
397 ± 159t 424 ± 146t
303 ± 147:\: 298 ± 142
1.5± 1.0 16 ± 1.2
84 ± 15 79 ± 14:\:
103 ± 14:\: 101 ± 14t
119 ± 20 120 ± 17
130 ± II 130 ± II
149 ± 15:\: 145 ± 15:\:
169 ± 19 167 ± 21t
Diltiazem
360 mg/day Placebo 360 mg/day
4.9 ± 7.3t 9.3 ± 7.1 3.1 ± 3.0t
3.9 ± 7.2t 5.9 ± 5.2 1.7 ± 2.4:\:
473 ± 149t. 418 ± 172 508 ± 158:\:
344 ± 132t. 347 ± 153 404 ± I53:\:
I 7 ± I I 1.8 ± 1.2 1.7± 1.2
80 ± 14:\: 84 ± 17 75 ± 13t
97 ± 15t. 102 ± 18 93 ± 14t
120 ± 18 123 ± 20 117 ± 18:\:
128 ± lIt 127 ± 16 126 ± 12
143 ± 13:\: 146 ± 18 143 ± 14
160 ± 21t 163 ± 25 162 ± 21
Anginal episodes per week
Nitroglycenn tablets per week
Treadmill time (seconds)
ST segment deviation
Onset (seconds)
Peak (mm)
Heart rate (beats/min)
Rest
Submaximal exercise
Peak exercise
Systolic blood pressure (mm Hg)
Rest
Submaximal exercise
Peak exercise
Rate-pressure product
(beats/min' mmHg . 10- 2)
Rest
Submaximal exercise
Peak exercise
Time to angina (seconds)
Placebo
11.9 ± 8.7
8.4 ± 8.7
320 ± 159
244 ± 115
1.6 ± I 0
87 ± 16
108 ± 15
122 ± 21
137 ± 19
161 ± 20
174 ± 24
119 ± 32
174 ± 38
215 ± 58
241 ± 143
110 ± 24
154 ± 32:\:
203 ± 51
335 ± 176t
103 ± 23:\:
146 ± 28t
201 ± 42
350 ± 135t
103 ± 19:\:
138 ± 29t.
192 ± 41
379 ± 185t
107 ± 23
149 ± 39
206 ± 51
349 ± 179
95 ± 18:\:
134 ± 28:\:
190 ± 32:\:
416 ± 189:\:
*p < 0.05 vs. next lower dose of diluazern. tp < 0.001 vs. placebo :\:p < 005 vs. placebo
700
as compared with placebo (p < 0.001). A similar improve-
ment (38%) was observed during the double-blind phase.
The time to onset of angina and onset of ST segment depres-
sion was significantly prolonged in both the single-blind and
double-blind phases of the protocol.
Electrocardiographic effects. The PR interval at rest
increased from 157 ± 24 ms on placebo to 167 ± 25, 168
± 23 and 173 ± 26 ms on 120, 240 and 360 mg per day
diltiazem, respectively (p < 0.01). No significant changes
in the QRS or QT intervals were observed. The amount of
ST segment depression at peak exercise was unaffected by
diltiazem (Table I).
Comparison of various dosages of diltiazem.
Increasing doses of diltiazem resulted in additional reduc-
tions in anginal attacks and nitroglycerin consumption and
improvement in exercise tolerance. When the 360 mg daily
dose of diltiazem was compared with the 240 mg daily dose,
the heart rate and rate-pressure product were significantly
reduced during submaximal exercise (Table 1). When dil-
tiazem was increased from 240 to 360 mg per day, both the
onset of ST segment depression and the total treadmill time
were significantly prolonged, with the majority of patients
(85%) demonstrating a further increase in treadmill time,
and nine patients (45%) showing both an increase in tread-
mill time and a decrease in the number of anginal attacks.
Effects of placebo (Table 2). During phases I and II of
the study, each patient underwent a total of 10 exercise
tests. One was performed just before entry into the study
(the control test) and five other tests were performed while
• p < 005
as compared
to placebo
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all doses of diltiazem during the single- and double-blind
phases. At peak exercise, the heart rate and rate-pressure
product produced were reduced only during the double-blind
phase. The systolic blood pressure at submaximal and max-
imal exercise was only reduced during the dose titration
period (phase I).
Exercise performance (Table 1). Treadmill time was
significantly increased by diltiazem: 33% on 120 mg per
day, 50% on 240 mg per day and 67% on 360 mg per day,
Figure 2. Treadmill exercise time and time to ST segment depres-
sion during the double-blind and open label phases of the study.
Values are expressed as mean ± standard deviation. Numbers in
parentheses represent the number of patients evaluated.
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the patient was taking placebo (Fig. 1). There were no
differences in any of the variables measured between the
control exercise test and the initial placebo test. However,
when the first placebo evaluation was compared with the
last, there was a significant decrease in the number of an-
ginal attacks and the submaximal rate-pressure product, and
an increase in treadmill time and onset of ST segment
depression was observed.
Adverse reactions. All doses of diltiazem were ex-
tremely well tolerated. Two patients had transient flushing,
two had mild pedal edema and four developed first degree
atrioventricular block (PR interval = 0.20 to 0.22 second).
No side effect was severe enough to necessitate a reduction
in the dosage or discontinuation of the medication.
Long-term follow-up. Twenty patients were maintained
on diltiazem, 360 mg per day, after completion of the first
two phases of the study. One patient dropped out of the
study after 4 months of open label drug therapy because of
the development of unstable angina requiring additional
medication. Three patients were withdrawn because they
underwent elective coronary bypass surgery in accordance
with the preference of their referring physicians, despite
continued good clinical response to diltiazem. One other
patient refused to take medication because of the disap-
pearance of his anginal symptoms.
Treadmill testing on the patients remaining in the study
demonstrated a persistent increase in treadmill time and time
to ST depression (Fig. 2). No new adverse drug response
was noted at any time during the follow-up phase.
Discussion
Effectiveness of diltiazem therapy. Diltiazem has been
used extensively with good efficacy for the treatment of
vasospastic angina (1-4,18). Several studies (5-14) recently
reported on its efficacy for exertional angina. Using a single
dose of 90 mg of diltiazem, one group demonstrated a pro-
longed time to angina and ST depression (14), and two other
studies using 120 mg doses have shown beneficial effects
(13,19). Two multicenter clinical trials (7,12) evaluating
the efficacy of diltiazem have been reported recently. Both
trials using doses of 240 mg per day demonstrated that
diltiazem prolonged exercise time, time to angina and time
to ST depression compared with placebo and had mild in-
frequent side effects.
We found that 360 mg per day was well tolerated. Al-
though the clinical response to this dose was similar to the
240 mg per day dose, most of our patients had a further
increase in exercise time and time to ST segment depression
compared with the more frequently studied dose of 240 mg
per day. This effect was persistent during the follow-up
period of 6 months without major side effects. One recent
study (20) also found subjective and objective improvement
with three different doses of diltiazem as compared with
placebo; the best reduction of anginal attacks and enhance-
ment of exercise capacity was observed with a 360 mg per
day dose.
Mechanism of antianginal effect. The results of this
study provide insight into the mechanism of action of dil-
tiazem in patients with exertional angina. When the patients
were taking diltiazem, they generally exercised longer and
had a lower rate-pressure product at rest and throughout
exercise. This suggests that the antianginal effect of dilti-
azem could be explained by a reduction in myocardial ox-
ygen demand at a given external work load. Diltiazem also
caused a significant reduction of the heart rate at rest, but
none of our patients demonstrated severe bradycardia.
Plasma diltiazem levels varied greatly after a given dos-
age, which may be attributable to its variable liver metab-
olism. This high interpatient variability probably caused the
lack of correlation between blood levels and response, al-
though the mean blood levels increased concomitantly with
increasing dosages.
Table 2. Effects of Placebo on Clinical and Exercise Performance
Control Placebo p Value
Week
Week 0 Week 2 Week 5 Week 7 or II Week 9 Week 12 2 vs. 12
Anginal episodes per week 10.4 ± 3.7 11.9 ± 8 7 10 4 ± 8.2 93 ± 7.1 105 ± 8 3 8.2 ± 9.0 < 0.05
Nitroglycerin tablets per week 7.9 ± 35 8.4 ± 8.7 7.3 ± 7.9 5.9 ± 5.2 7.8 ± 8.6 5.4 ± 7.8 NS
Treadmill time (seconds) 306 ± 118 320 ± 159 330 ± 162 418 ± 172 373 ± 172 403 ± 185 < 0.01
Onset of ST 230 ± 115 244 ± 115 254 ± 142 347 ± 153 311 ± 165 328 ± 164 < 0.01
depression (seconds)
Rate-pressure product
(beats/min' mm Hg > 10- 2)
Rest 121 ± 35 119 ± 32 119 ± 28 107 ± 23 110 ± 23 109 ± 26 NS
Submaximal exercise 177 ± 57 174 ± 38 159 ± 44 150 ± 39 150 ± 35 148 ± 30 < 0.001
Maximal exercise 217 ± 57 215 ± 58 195 ± 56 206 ± 51 201 ± 47 206 ± 47 NS
NS = not significant.
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Effecton exercise performance. Multiple exercise test-
ing can lead to enhanced exercise performance, as has been
shown in our study and others (6,21-23). Although the
baseline control exercise test was not different from the first
placebo test, there was an increase in the treadmill time and
onset of ST segment depression and a decrease in the sub-
maximal rate-pressure product when the last placebo test
was compared with the first. Several explanations may ac-
count for these changes. Increasing familiarity of the pa-
tients with the equipment and exercise protocol may lead
to enhanced exercise capacity. In addition, a drug carryover
effect may have been observed, as several of the placebo
tests occurred 1 week after diltiazem was discontinued. Fi-
nally a training effect from repeat exercise tests may have
occurred-this is suggested by the decrease in the submax-
imal rate-pressure product. Despite these effects, diltiazem
caused an additional 63% reduction in anginal attacks and
a 22% increase in treadmill time compared with the best
values on any of the placebo tests.
Limitations of study. The results of this study should
be interpreted on the basis of certain limitations inherent in
the study design. First, the comparisons among the different
doses could only be performed during the single-blind phase.
The patients also received more study tablets while receiving
the higher doses. Second, patients were maintained on each
incremental dose for a single week, which conceivably could
have prevented the full effect of that particular dose. Finally,
a "training effect" cannot be ruled out as a contributing
factor to the increased exercise tolerance observed during
increasing doses of diltiazem.
Implications. We conclude that diltiazem is an effective
agent in the treatment of exertional angina. Our study sug-
gests that in patients whose response to 120 mg per day is
suboptimal. the dose can be safely increased to 240 or 360
mg per day with the expectation of added beneficial effects.
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